Adam Hochron

When a patient gets bitten by a dog, there can be many issues doctors need to confront as treatment begins. Two doctors shared their experiences of a patient who was bitten by a dog and still had symptoms including swelling and pain 2 weeks after his K-9 encounter.

As the practice of telecare continues to gain momentum, a group of researchers conducted a study to test how effective that course of treatment is in patients with chronic illnesses.

As the life expectancy of patients continues to grow, healthcare professionals are seeing a rise in cases of osteoarthritis in their case files and are charged with discovering the best treatment possible for them.

The Ebola outbreak in West Africa continues to expand and around the world researchers are striving to learn more about the disease and how to stop it to ensure that any future outbreaks of the virus are not nearly as severe.

When a patient arrives at a hospital or other urgent care center, there are seemingly endless tests that can be undertaken to appropriately diagnose the patient. A recent study reviewed the necessity of some tests, particularly in regard to acute, nonspecific lower back pain.

Researchers from the National Institute of Allergy and Infectious Diseases and GlaxoSmithKline will soon launch phase I clinical trials of experimental Ebola vaccines.

Researchers at ETH Zurich who were studying mice with rheumatoid arthritis found a product that cured the animals of the condition as a precursor to what could be a much larger and beneficial discovery for humans. A statement from the company said the therapy is an "active substance consisting of two fused components."

Although hemodialysis is a commonly used treatment for kidney failure, a recent study has shown it may not be as beneficial for people who develop a sudden case of the condition.

CDC Director Thomas Frieden, MD, visited Liberia to assess ongoing efforts to contain the Ebola outbreak and reported that the current prevention and treatment response has unable to stop the virus from spreading.

When patients seek medical attention for symptoms such as headaches or seizures that could be caused by a range of underlying conditions, the process of arriving at an accurate diagnosis can be quite challenging for health care professionals. One recent study has shown that making the wrong diagnosis in these situations can cause considerable harm.

Efforts to combat the ongoing Ebola outbreak in West Africa have gone global as Japan recently announced efforts to provide medical assistance to the cause.

Researchers in Great Britain and Australia believe they have found a commonality that could help the treatment of two types of diabetes.

The guidelines were developed as part of a multi-part plan to curb misuse, abuse, and diversion of opioid medication by preventing opioid medications from being inappropriately prescribed in the emergency department, and by reducing the overuse of emergency departments for pain relief.

According to the results of a recent study, hospitalized patients may be able to know well in advance whether they are at risk of being diagnosed with type 2 diabetes in the future.

Clinicians may one day be able to offer more effective, personalized treatment to patients diagnosed with lupus thanks to a potential breakthrough in DNA sequencing.

One-pill regiment includes abacavir, dolutegravir and lamivudine.

The US Food and Drug Administration recently announced the approval of the KRONUS Zinc Transporter 8 Autoantibody (ZnT8Ab) ELISA Assay, a new test for type 1 diabetes.

The first two Americans to be treated for the Ebola virus on US soil became the first American patients to be discharged from the hospital where they had been kept in isolation for treatment from the virus.

Between developing its own pipeline of therapies for patients with hepatitis C and acquiring another company known for its work in this field, it looks like Merck is taking steps to be a larger player in HCV market.

As the 2 Americans stricken with Ebola continue to receive treatment in Atlanta, a new potential case of the deadly virus has been reported in California.

Every year, more and more Americans are diagnosed with type 2 diabetes mellitus and, according to a recent study, in the near future that number could reach close to 40% of the population.

A new drug was given tentative approval by the US Food and Drug Administration to help patients with both type 1 and type 2 diabetes.

As the number of people falling victim to the most recent outbreak of the Ebola Virus continues to rise past 1000, aid workers' focus has begun to shift to preventing the spread of Ebola beyond the African continent.

The massive media coverage of the Ebola virus outbreak in West Africa and the coordinated efforts to keep it from spreading has created fertile ground for online scammers peddling so-called Ebola treatments.

With the help of a grant from the National Institutes of Health, Profectus Biosciences Inc. of Tarrytown, NY, is looking to became one of the key players as medical science looks for a way to prevent future outbreaks of the Ebola Virus.

Following news that two American Ebola patients were successfully treated with ZMapp, an experimental medication that has not been tested in humans, advocates and aid groups have called for ZMapp and other experimental medications to be made available to the hundreds of patients in West Africa who are still battling the virus.

While doctors and researchers have been busy studying what has caused the most recent outbreak of the Ebola virus and how to stop it, one thing most agree on is that the risk of airborne infection is minimal at best.

As the African Ebola outbreak continued to spread across West Africa, infecting thousands of people (including at least three Americans so far), the US House of Representatives held a hearing this week to discuss the country's response to the deadly disease.

In just a few short years the number of doctors and hospitals using electronic health records has grown dramatically, according to the US Department of Health and Human Services.

Researchers at Auburn University are joining what is becoming a crowded field of teams looking to develop a drug to treat future outbreaks of the Ebola virus.